

Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC held on Monday, 27th April 2026 at 3.00 PM at its Corporate Office at Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka -1223 has approved the Un-audited 3rd Quarterly Financial Statements of the Company for the period ended 31st March 2026 and has taken the following decisions:

1) Financial Information:

Earning Per Share (EPS)	: Tk. 5.95
Net Asset Value Per Share (NAVPS)	: Tk. 33.55
Net Operating Cash Flow Per Share (NOCFPS):	Tk. 9.45

2) The Comparative statement of financial information:

Particulars	Jul'25-Mar'26	Jul'24-Mar'25	Jan'26-Mar'26	Jan'25-Mar'25
Earning Per Share (EPS)	Tk. 5.95	Tk. 3.75	Tk. 1.22	Tk. 0.28
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 9.45	Tk. 5.45	-	-

Particulars	As at 31 Mar' 26	As at 30 Jun' 25
Net Asset Value Per Share (NAVPS)	Tk. 33.55	Tk. 28.86

Date : 27-04-2026

By the order of the Board of Directors

BEACON[®]
Pharmaceuticals PLC

BEACON Business Centre:
9/B/2 Toyenbee Circular Road, Motijheel, Dhaka-1223

S/D

Md. Sahabuddin FCS
Company Secretary